Germany - Antineoplastic and immunomodulating agents

Description

For the active substance pemetrexed (ATC code: L01BA04), for parenteral preparations of finished medicinal products in oncology manufactured in pharmacies for direct medical use, the AOK - Die Gesundheitskasse für Niedersachsen offers all interested pharmaceutical companies discount contracts for the period until the entry into force of exclusive contracts following a formal award procedure in accordance with the rules of Part 4 of the ARC, without a selection decision. The contracts are concluded within the framework of an "open-house model" and act as a bridge between the beginning of generic competition (patent expiry) and the award of exclusive contracts. The offered contracts are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. In the open-house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform - individual negotiations are generally not conducted. The term of the contract shall be a maximum of twenty-four months, the earliest commencement date of the contract being 1.3.2019. All contracts shall expire on 28.2.2021 at the latest, irrespective of the date on which the contract was concluded. An accession or a contract conclusion can take place within the twenty-four month period in each case to the first of a month. There is a right of termination six weeks to the end of each month. The AOK - Die Gesundheitskasse für Niedersachsen reserves the right to replace the non-exclusive open-house discount contracts with exclusive discount contracts during the term of the contract. When exclusive discount contracts put out to tender come into force, the open-house contracts are terminated in accordance with the contractual provisions, i.e. the open-house contracts end automatically. Interested pharmaceutical companies can request the contract documents as well as the contractual conditions from the contact address given under I.1).Contracts for the active substance pemetrexed (ATC code: L01BA04), for parenteral preparations of finished medicinal products in oncology manufactured in pharmacies for direct medical use, will be concluded for the first time with effect from 1 March 2019. Interested parties who wish to become contractual partners by this date must submit the contract documents to be submitted to the address specified in the contract documents by 31.1.2019. It depends on the access to the AOK Niedersachsen. Contracts may be concluded at a later date during the maximum twenty-four-month period, beginning on the first day of each month. In terms of organisation, the AOK usually needs a preliminary run of 35 calendar days in order to be able to guarantee the necessary work, e.g. the notification of the contract in the Lauer-Taxe®. The exact deadlines for receipt will be announced together with the contract documents. This publication does not constitute the award of a public contract within the meaning of the Public Procurement Coordination Directive (2004/18/EC) or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, publication shall take place in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form, the contract notice shall be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this announcement form and the publication platform. This does not imply any further significance, in particular subordination to subcontracting regulations, unless they are mandatory for legal reasons.

Opportunity closing date

28 December 2020

Value of contract

to be confirmed